d path af=er our last meeting, but they've hit a few roadblocks. We think it's worth=a follow-up. The other companies suggested - Calixa, Novadyne, Alphavax - are more matur= and/or we've exited. In other words, we aren't actively engaged in these =ompanies. I've copied Risa Stack, one of our Life Scien